Navigation Links
QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
Date:2/19/2009

MoxDuo(TM) IR in patients following total knee replacement. No additional pharmacology, toxicology or long-term clinical safety studies will be required for regulatory submission and market approval.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty

pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, MoxDuo(TM) IR, successfully completed a Phase 3 study and met primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, please visit www.QRxPharma.com.'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 Contract Research Organization ... to relocate into a new 41,500 ft2 facility. The ... currently located at 16825 W. 116th St. in Lenexa, KS. ... times the customized laboratory space, will remain in the Kansas ... was founded more than twenty years ago. Remaining in ...
(Date:4/21/2015)... , April 21, 2015 ... and development, custom automation, and contract manufacturing, and  ... accessible flow cytometry and cell sorting technology for ... develop a novel flow cytometry platform. ... NanoCellect Biomedical has developed a microchip-based cell sorting ...
(Date:4/21/2015)... LEXINGTON, Mass. , April 21, 2015 ... company developing transformative pharmaceutical products for subcutaneous ... its pivotal trial of its investigational proprietary ... treatment of edema associated with congestive heart ... development, scPharmaceuticals is developing a proprietary patch ...
(Date:4/21/2015)... 2015 Leading-edge research into ... will be presented at the 2nd International ... and clinicians from academia, industry and government ... Invibio Biomaterial Solutions. The world-leading solutions provider ... manufacturing and R&D for medical-device manufacturers, holds ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3
... to Build Upon 2007 ... Record-Breaking Results, NEW YORK, Dec. 20 Underscoring ... breast cancer, the Avon,Foundation today announced the 2008 Avon Walk for Breast ... expand into a,ninth market -- Houston -- to build upon the momentum ...
... 20 ISTO Technologies, Inc., a privately,held orthobiologic company, ... Forum in San Francisco, CA from January 7-8, 2008.,Mitchell ... present on,Tuesday, January 8th at 11:00 a.m. Pacific Time, ... Information about the OneMedPlace Finance Forum may,be found at ...
... 20 CuraGen Corporation,(Nasdaq: CRGN ), a ... appointment of Sean Cassidy, as Vice,President and Chief ... today that David M. Wurzer will step down ... other opportunities, but will remain,with the Company through ...
Cached Biology Technology:Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3CuraGen Corporation Announces Appointment of Sean Cassidy as CFO 2CuraGen Corporation Announces Appointment of Sean Cassidy as CFO 3CuraGen Corporation Announces Appointment of Sean Cassidy as CFO 4
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... 2014) -- There are more than a trillion cells called ... Each of these neurons contains millions of proteins that perform ... complex networks of the brain still remains as a mystery ... first time, a group of scientists has been able to ...
... wild-caught caterpillars, its food plants and parasitoids, has been going ... Conservacin Guanacaste (ACG), a protected area of approximately 1200 ... 10,000 species of moths and butterflies are estimated to live ... parasitoid wasps, also numbering thousands of species. However, most of ...
... Engineering (NCE) at New Jersey Institute of Technology (NJIT) will host ... in the Campus Center Atrium. Proceeds from the event will ... NCE Dean,s Fund. "NCE has a long tradition ... them hands-on experiences along the way," said Interim Dean Basil C. ...
Cached Biology News:Watching how the brain works 2Almost 200 new species of parasitoid wasps named after local parataxonomists in Costa Rica 2NJIT's Newark College of Engineering announces honorees for annual Salute to Excellence 2NJIT's Newark College of Engineering announces honorees for annual Salute to Excellence 3
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... Formula variant: With the ... by Murashige and Skoog (1962) ... by Gamborg, et al. (1968). ... contain 4.4 grams of powder ...
... Endostatin. Canine Cytokine EIA Kits,(Competitive ... a line of enzyme-linked immunosorbent assay ... for multiple research applications. The line ... quick and dependable assays. The quantitative ...
... Formula variant: With the ... described by Hoagland and ... Equivalency: Formulated to contain ... powder per liter of ...
Biology Products: